PURE Bioscience, Inc. has called its 2026 annual meeting for February 17, 2026 in Huntington Beach, CA. Stockholders will vote on four key items: electing seven directors, ratifying Weinberg & Company, P.A. as auditor for the year ending July 31, 2026, holding a non-binding advisory vote on executive compensation, and approving an amendment to increase authorized common stock from 200,000,000 to 250,000,000 shares.
The company explains that it relies on equity and convertible debt financings to fund operations and raised $1,015,000, $1,785,000 and $2,000,000 of convertible debt in fiscal 2023, 2024 and 2025. It argues that additional authorized shares would provide flexibility for future capital raising, acquisitions and equity awards. Executive pay is positioned as modest, with voluntary salary reductions for senior leaders, no cash bonuses in 2024 or 2025, and compensation heavily tied to stock options.
The Board highlights its governance structure, independent Audit and Compensation Committees, director qualifications, and insider trading and ethics policies. It unanimously recommends voting FOR all director nominees and FOR Proposals 2, 3 and 4.
PURE Bioscience, Inc. reported results for the three months ended October 31, 2025, with modest sales growth but ongoing losses and a weak balance sheet.
Total revenue reached $708,000, up from $556,000 a year earlier, as net product sales rose across its customer base. Gross profit improved to $450,000 and gross margin increased to 64%, helped by higher-value packaging. Operating expenses fell to $829,000, mainly from lower selling, general and administrative costs.
Despite these improvements, PURE recorded a net loss of $464,000 and used $250,000 in operating cash. Cash and cash equivalents were only $434,000 at October 31, 2025, against current liabilities of $3,159,000 and a stockholders’ deficiency of $5,546,000. Management and the independent auditor highlight substantial doubt about the company’s ability to continue as a going concern, noting reliance on related-party convertible notes totaling $5,677,000 that are currently convertible into 46,563,461 shares of common stock.
PURE Bioscience, Inc. filed a current report to notify investors that it has issued a press release announcing financial results for its fiscal first quarter ended October 31, 2025. The press release, dated December 15, 2025, is included as Exhibit 99.1 and contains details about the company’s operations and financial condition for that period.
The company explains that this information is being furnished rather than filed, so it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC documents.
Pure Bioscience, Inc. officer Jeffrey Scott Kitchell, who serves as President and Corporate Secretary, reported his beneficial ownership of company securities as of 11/17/2025. He directly holds 12,998 shares of Pure Bioscience common stock. In addition, he holds several stock option awards giving him the right to buy common shares at exercise prices ranging from $0.07 to $0.79 per share, with expiration dates extending through 2034. Earlier option grants from 2020 through 2024 are already fully vested, while an option granted on September 23, 2025 for 300,000 shares is scheduled to vest in four equal installments on December 23, 2025, March 23, 2026, June 23, 2026, and September 23, 2026.
PURE Bioscience, Inc. announced a leadership change in its executive team. Jeffrey Kitchell has been appointed as the company’s President, effective November 17, 2025, while continuing in his existing role as Corporate Secretary. Robert Bartlett remains Chief Executive Officer, principal executive officer, and a member of the board, but no longer holds the President title.
Kitchell, age 55, has been Vice President of Operations since April 2023 and has served as Corporate Secretary since 2019. He has been with the company since 2001 in a variety of roles overseeing day-to-day operations, legal affairs, and intellectual property, and holds a Bachelor’s degree in Business Administration from the University of Phoenix. His compensation terms are expected to follow the company’s standard officer indemnification and benefit programs, with no new special arrangements or related-party relationships disclosed.
PURE Bioscience, Inc. filed its annual report for the year ended July 31, 2025. The company reported net product sales of $2.20 million, up from $1.96 million in 2024, and a net loss of $2.4 million versus a $3.4 million loss last year. Cash was $334,000 as of July 31, 2025, and auditors expressed substantial doubt about the company’s ability to continue as a going concern.
The business focuses on proprietary silver dihydrogen citrate (SDC) antimicrobial products, including PURE Hard Surface (EPA-registered) and PURE Control (FDA Food Contact Notifications for poultry and produce). Customer concentration remains notable; the largest customer represented 18% of net product sales in 2025. As of October 29, 2025, there were 111,886,473 shares outstanding. The company completed a private placement of convertible debt with $2.0 million in net proceeds during fiscal 2025 and indicates the need for additional capital to fund operations.
PURE continues to pursue food-safety markets through distributors and partnerships while navigating extensive regulatory requirements from the EPA, FDA, USDA and foreign authorities.
PURE Bioscience (PURE) furnished an 8‑K under Item 2.02 announcing a press release with financial results for the fiscal year ended July 31, 2025. The press release is attached as Exhibit 99.1. The company states the information is being furnished, not filed, and will not be incorporated by reference into other SEC filings.